Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03617510
Other study ID # BALF-PAIN-1002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 10, 2018
Est. completion date April 30, 2019

Study information

Verified date July 2020
Source Shijiazhuang Yiling Pharmaceutical Co. Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. To evaluate the tolerances of healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose

2. To evaluate the pharmacokinetic characteristics in healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose

3. To provide the basis for the dose for the follow-up clinical study.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date April 30, 2019
Est. primary completion date November 5, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions;

2. Be able to complete the research according to the clinical trial protocol;

3. Subjects have no pregnancy plan within the next 6 months and voluntarily take effective contraceptive measures;

4. Male and female subjects between 18 and 45 years (inclusive) of age;

5. Male subjects weighing no less than 50 kg, female subjects weighing no less than 45 kg.Body Mass Index (BMI) 18 to 28 kg/m2 (inclusive);

6. Physical examination, vital signs normal or no clinical significance.

Exclusion Criteria:

1. Someone smoking more than 5 pieces per day within the 3 months before the trial ;

2. Allergies, such as allergies to two or more drugs, food and pollen, or known to the drug component or ethylbenzene ethyl acetate allergy;

3. Having a history of drug and / or alcohol abuse (14 units of alcohol per week: 1 units = beer 285 mL, or 25 mL of spirits, or 100 mL of wine);

4. Blood donation or extensive blood loss (> 400 mL) within three months of the use of the study drug;

5. Taked any drug that changes liver enzyme activity 28 days prior to the use of the study drug;

6. Taked any prescription, OTC drugs, any vitamin products or herbs within 14 days prior to the use of the study drug;

7. Two weeks before the trial took a special diet (including dragon fruit, mango, grapefruit, and / or rich in xanthine diet, etc.) or strenuous exercise, and other avtivites that affect drug absorption, distribution, metabolism, excretion and so on;

8. Combined with the following CYP3A4, p-gp or Bcrp inhibitors or inducers, such as itraconazole, ketoconazole or dronedarone;

9. There have been significant changes in diet or exercise habits recently;

10. Taked research drugs within three months prior to the use of the study drug or participating in any drug clinical trial;

11. Suffering from any increased risk of hemorrhagic disease, such as hemorrhoids, acute gastritis or stomach and duodenal ulcers;

12. ECG has clinical significance;

13. Female subjects are in lactation or serum pregnancy test are positive during screening or during the test.

14. Clinical laboratory tests are abnormal and have clinical significance, or other clinical findings showing clinically significant diseases (including but not limited to gastrointestinal, renal, liver, nerves, blood, endocrine, neoplasms, lungs, immunizations, mental or heart Cerebrovascular disease);

15. hepatitis (including hepatitis B and hepatitis C), AIDS, syphilis screening test positive;

16. Acute disease occurs before screening or using test drug;

17. Taking chocolate, any caffeine, or xanthine-rich food or drink at least 48 hours prior to the use of the study drug;

18. Taking any alcoholic products within 24 hours prior to the use of the study drug;

19. Alcohol or drug screening positive or drug abuse history over the past five years or 3 months before the trial used by drug users.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Felbinac Trometamol Injection
Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
Placebos
Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.

Locations

Country Name City State
China The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Shijiazhuang Yiling Pharmaceutical Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tolerance evaluation index percent of subjects with adverse reactions up to 96.5 hours after mutil-dose
Secondary Tmax The amount of time that a drug is present at the maximum concentration in serum. up to 96.5 hours after mutil-dose
Secondary Peak Plasma Concentration (Cmax) The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
Secondary t1/2 The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
Secondary Vd The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
Secondary Mean residence time (MRT) parameter. The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
Secondary Ke The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
Secondary Area under the plasma concentration versus time curve (AUC0-8) The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
Secondary AUC0-48 The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
Secondary Ae0-48 The PK parameters of the urine and the stool sample up to 96.5 hours after mutil-dose
Secondary AUC0-last The PK parameters of the plasma sample up to 96.5 hours after mutil-dose
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Recruiting NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care